Circulating tumor DNA (ctDNA) as predictive biomarker in NSCLC patients treated with Nivolumab

Marta Castiglia; Angela Listi'; Antonio Russo; Francesco Passiglia; Alessandro Perez; Chiara Ancona; Emmanuela Musso; Sergio Rizzo

Circulating tumor DNA (ctDNA) as predictive biomarker in NSCLC patients treated with Nivolumab

Marta Castiglia, Angela Listi', Antonio Russo, Francesco Passiglia, Alessandro Perez, Chiara Ancona, Emmanuela Musso, Sergio Rizzo

Risultato della ricerca: Other › peer review

Abstract

Nivolumab is a programmed death-1 (PD-1)inhibitor recently approved for the treatment of NSCLC patients who failed prior chemotherapy. Searching for predictive biomarkers of immunotherapy efficacy is an area of intensive investigation for translational research. Monitoring circulating tumor DNA (ctDNA) during nivolumab treatment could help clinicians to predict the immunotherapy efficacy and ultimately improve the management of patients

Lingua originale	English
Numero di pagine	0
Stato di pubblicazione	Published - 2017

Altri file e collegamenti

OA Link

Cita questo

@conference{5e77de80376841368cf989fd526cc7c7,

title = "Circulating tumor DNA (ctDNA) as predictive biomarker in NSCLC patients treated with Nivolumab",

abstract = "Nivolumab is a programmed death-1 (PD-1)inhibitor recently approved for the treatment of NSCLC patients who failed prior chemotherapy. Searching for predictive biomarkers of immunotherapy efficacy is an area of intensive investigation for translational research. Monitoring circulating tumor DNA (ctDNA) during nivolumab treatment could help clinicians to predict the immunotherapy efficacy and ultimately improve the management of patients",

author = "Marta Castiglia and Angela Listi' and Antonio Russo and Francesco Passiglia and Alessandro Perez and Chiara Ancona and Emmanuela Musso and Sergio Rizzo",

year = "2017",

language = "English",

}

TY - CONF

T1 - Circulating tumor DNA (ctDNA) as predictive biomarker in NSCLC patients treated with Nivolumab

AU - Castiglia, Marta

AU - Listi', Angela

AU - Russo, Antonio

AU - Passiglia, Francesco

AU - Perez, Alessandro

AU - Ancona, Chiara

AU - Musso, Emmanuela

AU - Rizzo, Sergio

PY - 2017

Y1 - 2017

N2 - Nivolumab is a programmed death-1 (PD-1)inhibitor recently approved for the treatment of NSCLC patients who failed prior chemotherapy. Searching for predictive biomarkers of immunotherapy efficacy is an area of intensive investigation for translational research. Monitoring circulating tumor DNA (ctDNA) during nivolumab treatment could help clinicians to predict the immunotherapy efficacy and ultimately improve the management of patients

AB - Nivolumab is a programmed death-1 (PD-1)inhibitor recently approved for the treatment of NSCLC patients who failed prior chemotherapy. Searching for predictive biomarkers of immunotherapy efficacy is an area of intensive investigation for translational research. Monitoring circulating tumor DNA (ctDNA) during nivolumab treatment could help clinicians to predict the immunotherapy efficacy and ultimately improve the management of patients

UR - http://hdl.handle.net/10447/245238

M3 - Other

ER -

Circulating tumor DNA (ctDNA) as predictive biomarker in NSCLC patients treated with Nivolumab

Abstract

Altri file e collegamenti

Fingerprint

Cita questo